NEW YORK (GenomeWeb News) – Fluidigm reported after the close of the market Wednesday that its third-quarter revenues increased 21 percent year over year driven by strong consumables growth.

The firm also said in a separate announcement Wednesday that it has filed litigation against NanoString Technologies alleging deceptive marketing practices in an advertising campaign for its nCounter gene expression assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.